Bristol Myers Squibb Reports Positive CAR T-Cell Therapy Results for Multiple Myeloma

Bristol Myers Squibb announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel), a GPRC5D-directed CAR T cell therapy for heavily pretreated patients with quadruple-class exposed relapsed and refractory multiple myeloma. The trial met its primary endpoint of overall response rate and key secondary endpoint of complete response rate.